Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Organovo Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

CEO

Organovo Holdings CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Keith Murphy	Executive Chairman	4.3yrs	US$789.99k	0.58% $ 41.3k
Thomas Hess	President & CFO	3yrs	US$199.32k	Veri yok
Vaidehi Joshi	Director of Discovery Biology & Director	2.5yrs	US$119.05k	0.13% $ 9.0k
Curtis Tyree	Senior Vice President of Strategy & Business Development	2.7yrs	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ONVO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Keith Murphy	Executive Chairman	4.3yrs	US$789.99k	0.58% $ 41.3k
Vaidehi Joshi	Director of Discovery Biology & Director	2.6yrs	US$119.05k	0.13% $ 9.0k
Adam Stern	Independent Director	4.3yrs	US$124.15k	0.13% $ 9.0k
Alison Milhous	Independent Director	4.1yrs	US$132.25k	0.13% $ 9.0k
Douglas Cohen	Lead Independent Director	4.1yrs	US$132.25k	0.21% $ 14.6k
David Gobel	Independent Director	4.1yrs	US$132.25k	0% $ 0

4.1yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ONVO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Organovo Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

High number of new and inexperienced directors

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

High number of new and inexperienced directors

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Recent updates

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş